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Abstract 
Cannabis is one of oldest cultivated plants used for medicinal purposes. The landscape of 
medical cannabis is rapidly expanding as more and more people push for its legalization. 
However, law-makers and politicians depress cannabis potential, claiming there is not enough 
evidence-based science behind the substance to convince them. Yet, in the United States, in 
order to study cannabis, the research has to be approved by multiple federal agencies through a 
rigorous and expensive processes. The federal barriers suppressing cannabis research and the 
government’s continuous call for cannabis prohibition has more ripple effects than expected. 
Cannabis prohibition affects the discovery of health benefits and risks of cannabis. Physicians, 
health professionals, and patients are advising dosages and types of cannabis without possessing 
the adequate knowledge, and without knowing the potential risks involved. As the acceptance 
and usage of cannabis and continues to grow in the United States, the demand for a more 
complete understanding on the substance is required. Until cannabis is rescheduled by the 
federal government, research will continue to be neglected and America will remain in the dark 
on mechanism, dosages, cannabinoids and many other uncertain aspects hidden within the 
complexity of cannabis. 
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Process Analysis Statement 
I did not know what “weed” was until I was a freshman in high school. It was 
everywhere; parties, concerts, parks, and even in my all-girls, private catholic school where girls 
managed to take a smoke break at lunch. However, I stayed far away. I was told that cannabis 
slowed down brain function, especially in girls. It could make you stupid, lazy, and depressed. 
Once recreational cannabis became legalized in 2012, old McDonald’s and abandoned buildings 
were turned into dispensaries and I was horrified: how was this horrible drug legal and able to be 
sold like liquor in a liquor store? 
It was not until I came back from freshman year of college that I completely changed my 
opinion. I saw how cannabis was helping my friends with their anxiety and depression. I saw 
how it was changing the lives of my mother’s friends with uncontrollable chronic pain. Creams, 
oils and lotions with cannabinol (CBD) took away muscle spasms. My town was booming from 
the influx of revenue that cannabis sales brought. I saw first-hand that all of the warning I 
received before were not completely true. The negative stigma that I harbored for years rapidly 
disappeared as cannabis configured into a normality and a part of my community.  
When I reflect back on how I felt about cannabis years ago, I am baffled: I used to hate, 
judge and shame people for partaking in it, but now, I am almost an advocate for it. For my 
honors thesis, I wanted to address those individuals whom I used to be like. For those who have a 
negative stigma regarding cannabis, I want to educate you. It is not my intention to force you to 
change your mind or tell you that you are wrong, I want to provide you with correct information, 
data, and trial evidence. I want to provide you the knowledge so that you can formulate your own 
opinion about cannabis. In addition, I wanted to highlight the repercussions of cannabis 
prohibition that are not normally talked about. Due to the restrictive federal drug laws on 
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cannabis, research and medical application is limited. We are unable to discover all of the 
potential health benefits that cannabis has to offer but most importantly, unable to understand 
and obtain a final consensus on the positive and negative side effects of cannabis.  
It is often forgotten the other goal of cannabis research is working towards an incredibly 
important cause: ending prohibition. Prohibition of cannabis has allotted for crime, drug 
production and distribution to be in control of criminals, unsafe substances that can contain and 
have adverse health effects and made room for a black-market. If the barriers of cannabis 
research are lowered, we will finally be able to fully understand what this substance, cannabis, 
truly is. 
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THE ANCIENT PLANT 
As one of humanity’s oldest cultivated crops, cannabis has a long and entwined historical 
geography. The exact origins of cannabis are uncertain but analyzation of botanical, ecological 
and archeological evidence suggests humans used cannabis thousands of years ago. 
Cannabis in Central China  
Hypothetical human use of cannabis can be traced all the way back to Central Asia. 
Ancient Chinese literature details how cannabis was domesticated from wild plants and 
cultivated into crops to be used as a source of food and textile fiber. Cannabis thrived in the 
favorable sunny, moist, well-drained and nutrient-packed soil. The fiber of the cannabis plant, 
hemp, was extracted from the stem and used to make rope, strong fabrics for clothing, fish-nets 
and paper. In 2727 BC, the Chinese Emperor, Shen-Nung, discovered the medicinal properties of 
cannabis and implemented them into his community. Shen-Nung was known to exploit various 
medicinal plants and other drugs derived from animals, minerals and vegetables to treat and cure 
illnesses. The widely considered “Father of Chinese Medicine”9 used cannabis and its seeds to 
treat aliments such as female menstruation, malaria, constipation and absent mindedness1. 
Cannabis was not used as a psychoactive drug during this time. Available literature does not 
reference explicit drug effects of the plant; poems, writings and medical texts honor cannabis 
solely for its’ medicinal properties. Shen-Nung is one of the first credited to discover the 
medicinal healing properties of cannabis. After Shen-Nung, cannabis became a stable in Chinese 
medicine for thousands of years. 
Ancient Chinese texts also refer to cannabis as a source of food. The same seed that was 
used to treat various illnesses and diseases could be ingested for its high nutritional value. 
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Legend claims that Buddha himself ate only one hemp seed a day and survived six years under 
the Bo Tree while he awaited enlightenment1. 
From China, cannabis then spread to India and became integral in their religion. 
Cannabis was deemed one of the five sacred plants used for “freedom from distress”. In the 
ancient Hindu scriptures, the Vedas, cannabis or “bhang” is described as a liberator and a source 
of happiness and joy. It was given to people to help attain delight and eradicate their fears1. 
Additionally, it was believed to be the Hindu God, Shiva’s, favorite food. Cannabis was 
typically ingested as a drink or smoked as a communal activity. 
European Trade 
Wild cannabis most likely diffused into Europe 3,500 years ago through Scythians as 
they moved from Central Asia through Russia34. However, it was not until the late 1700’s that it 
became a commodity of interest. Cannabis was reintroduced to Europe from the British East 
India Trading Company. Hemp from cannabis, along with other drugs such as opium, were 
goods traded from the East, Southeast Asia and India to England. William Brooke 
O’Shaughnessy, an Irish physician, learned about the medicinal uses of cannabis while abroad 
on an excursion with the company. In the late 1840’s, O’Shaughnessy instilled cannabis into his 
practices as an anti-inflammatory, antispasmodic, anticonvulsant, analgesic, and a sedative44. 
As cannabis spread throughout the world, from Asia to the West, it encountered almost 
every culture56. Further historical and archeological accounts of cannabis in places such as 
Brazil, Jamaica, India, South Africa, Colombia, Ethiopia and Amsterdam are also available for 
research.  
MARIJUANA IN AMERICA 
Colonial Cannabis 
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Cannabis first touched American soil in the 16th century when the initial colonies brought 
plants from Europe to the New World. Hemp produced from cannabis plants were a vital tool for 
emerging colonies as they struggled to survive in the unfamiliar land. The extracted hemp was 
used to make rope, cloth and paper. The various applications using hemp from cannabis 
compelled the leaders of the first colony in Jamestown, Virginia to pass a law requiring hemp to 
be grown on every farm in 1619. In addition to this law, hemp was allowed to be exchanged as 
legal currency in Virginia, Pennsylvania, and Maryland10 . 
During the 19th century, marijuana plantations in Mississippi, Georgia, California, 
Nebraska, and New York thrived. However, hemp harvesting was heavily labor intensive. It had 
to be processed by hand, forcing the procedure to be time consuming and costly. After the Civil 
War, newly developed products and imported goods slowly replaced the role of hemp and the 
plant fell out of popularity. In addition, the invention of the cotton gin during the Industrial 
Revolution completely overshadowed hemp and it failed to compete57. Cannabis regained 
recognition between the years 1850-1937 as it was used as a medicinal drug and was openly sold 
in pharmacies and general stores. In 1906, the Pure Food and Drug Act required labeling of any 
remedies containing cannabis5. 
Mexican “Marijuana” 
The Mexican Revolution in 1910 sparked an influx of Mexican immigrants into the 
United States. Between the years 1910-1930, more than half a million immigrants migrated from 
Mexico into America. War refugees and political exiles fled Mexico to escape the violence, 
bringing the habit of smoking cannabis with them. These immigrants called cannabis 
“marihuana” and for the first time, recreational cannabis use was being exercised in the 
American culture. Simultaneously, the temperance movements against alcohol instilled the 
 
6 
Volstead Act of 1920 which implemented the prohibition of production and distribution of 
alcoholic beverages. As alcohol became a pricey privilege, cannabis or “marihuana”, rapidly 
became an attractive substitute and lead to increased use in the drug.  Racists and anti-drug 
advocates associated cannabis with the unwanted, foreign citizens and campaigned against 
recreational cannabis; subsequently creating a negative stigma about cannabis to the public and 
lawmakers10. 
Although cannabis was not regarded as a consequential-major drug, several states banned 
the use of cannabis by the 1930’s. Claims were being made that cannabis caused men of color to 
become violent and solicit white women for sex10. Seven years later, the Marihuana Tax Act of 
1973 officially banned the use and sale of cannabis. In addition, the importation and cultivation 
were also heavily regulated. Importers had to endure a tedious clearance check along with paying 
a gruesome tax. Violation of the Act resulted in a $2,000 fine and imprisonment up to five 
years10. Scientific research on the medicinal properties and health benefits on the plant were 
halted as well.  
Hippies 
In the 60’s and 70’s, cannabis was a popular activity for activist groups fighting for rights 
and rejecting mainstream society. The term “dirty hippie” became associated with these 
individuals. The Marihuana Tax Act of 1937 was replaced by the Controlled Substance Act. This 
act established “schedules” for ranking substances according to their “dangerousness and 
potential for addition”14 and federally outlawed marijuana. President Nixon agreed to label 
cannabis as a Schedule 1 drug, the same category as heroin, LSD and ecstasy. Schedule 1 drugs, 
“have a high potential for abuse and the potential to create severe psychological and or/ physical 
dependence...with no currently accepted medical use…”14. Cannabis was termed medically 
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useless and research was restricted. This designation made it nearly impossible for any physician 
or scientist to conduct cannabis research and it solidified that cannabis would not be developed 
for medicinal use. 
Modern Cannabis  
Despite the recent classification of cannabis, California was the first state to legalize the 
medical use of cannabis. In 1996, it became legal to be administered as medicine for patients 
with cancer, AIDS, and other painful illnesses27. In addition, multiple journals and newspaper 
articles where petitioning for a rescheduling of cannabis from a Schedule 1 drug due to its 
medicinal properties. Simultaneously, former presidents Gerald Ford, Jimmy Carter and George 
Bush were urging voters to reject the medical marijuana initiatives and in 1997, the National 
Institute of Health stated that there is insufficient scientific evidence to “…definitively asses 
marijuana’s therapeutic potential…” They advised that the “…traditional scientific processes 
should be allowed to evaluate the drug’s use for certain disorders.”20 However, in 1998, Alaska, 
Oregon and Washington all legalized medical cannabis, removing the state-level criminal 
penalties on the possession, use and cultivation of cannabis for patients with prescriptions46. 
Vermont and the state of Washington were the first states to legalize recreational 
cannabis in 2012 with Colorado following soon after46. Today, cannabis has made astonishing 
advances with it being legal in some form in over thirty states in America. In addition, two 
cannabinoid-containing medications have been federally approved. Cannabis popularity 
continues to increase as activists push for the reconsideration of its scheduling and its 
legalization. However, research is still hindered due to the current classification and federal 
stature of cannabis, forcing the knowledge of its health potential to remain unknown. 
WHAT IS CANNABIS? 
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Botanical Description 
To introduce the controversial plant, it is important to paint an image of the cannabis 
plant. The anatomy of the cannabis plant, also known as hemp, is comprised of several 
structures. Cannabis grows long-skinny, green stems with the large, iconic fan leaves extending 
from its nodes. The cannabis plant can be distinguished as male, female or sometimes both. 
Female plants produce large, colorful flowers that can be trimmed down to reveal round or 
pointed buds. Male cannabis plants produce small pollen sacs near the base of the leaves. These 
pollen sacs, like most plant species, allow the male plant to pollinate the female plant, 
subsequently triggering the plant’s seed production. However, it is the seedless females, called 
sinsemilla, that are of interest for most cannabis cultivators because the flowers produced by a 
sinsemilla grow cannabinoid-rich buds. These buds are commonly used to unlock the 
psychoactive effects of the plant, and when people “smoke weed”, this is what they are ingesting. 
When a plant is both male and female, it is called hermaphroditic. Hermaphroditic plants possess 
the sex organs of both a female and male, allowing the plant to pollinate itself during its own 
flowering. 
The cannabis plant emerged almost 27.8 million years ago from Humulus, a plant genus 
responsible in giving beer its floral and bitter flavors. Both plants, cannabis and Humulus, make 
up the Cannabaceae family along with six other genera. However, when focusing on the genus 
Cannabis, there is no consensus on the taxonomy. For centuries, the taxonomy of cannabis at the 
species level has always been obscure. As a result of rising popularity, its taxonomy has become 
a more prevalent contentious issue. The “promiscuity” of the plant has blurred lineages 
boundaries36. The cannabis plant is capable of breeding with plants within its genus and can 
produce viable, complex offspring as a result. In addition, human cultivation and the cross 
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breading of naturally-wild cannabis plants with human-refined cannabis plants throughout the 
centuries has led its characterization to be a difficult task. However, categorization can still be 
attempted by examining the genotype (genetic makeup) and phenotype (physical traits) of a 
cannabis plant36. Some botanists argue there are three separate species of cannabis: Cannabis 
sativa, Cannabis indica and Cannabis ruderalis, while other botanists believe that C. indica and 
C. ruderalis are simply subspecies of their mother plant, C. sativa. 
Although it is unknown how and when the varying species of cannabis deviated and 
became separate entities, it is theorized to be from natural selection and where the seeds where 
farmed. It is certain that the environment altered the physical features of cannabis, leading to a 
new generation of cannabis plants and a diverse genus54. C. sativa is believed to originate from 
equatorial countries. The consistent year-round sun fostered taller and looser plants with finger-
like leaves compared to its counterparts. C. indica is generally short and stocky in stature with 
wider leaves. Native to sub-tropical countries, such as Pakistan and Afghanistan, C. indica 
dedicated all its energy to flowering when furnished with an adequate sun season. The 
combination of fast germination and flowering along with its small radius –which permits for a 
higher ratio of plants to useable space—has made C. indica idea for farmers and growers today. 
Lastly, the cannabis plant believed to have engendered from central Asia and Russia is called C. 
ruderalis. This species (or termed sub-species), was forced to adjust to the harsh climates and 
shorter viable-developing seasons. It is the shortest of the three, growing to one to two feet. 
Unlike the other species (or termed sub-species), the flowering cycle of C. ruderalis is auto-
flowering—meaning it is provoked by maturity. C. indica and C. sativa flowering is induced by 
light. 
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The morphological differences in branching, habitus, flowers and leaflets uncouples C. indica 
from C. sativa (see Appendix A) and C. ruderalis plants from the foremost. However, due to 
divergence from a common ancestor, C. indica, C. ruderalis and C. sativa nevertheless share 
similar characteristics, despite their dissimilar features.  
Hemp 
 Hemp, as mentioned before, is the substance extracted from the fibrous stalks of cannabis 
plants. When comparing the genus, C. sativa tends to be more fibrous than C. indica. 
Scientifically, hemp is the vernacular used to describe varieties and biotypes of the C. sativa 
plant that contain less than 0.3% delta-9 tetrahydrocannabinol, or commonly known as THC62. 
For centuries, the fibrous qualities of hemp were utilized in fabrics, textiles, yarns, paper and 
fish-nets for ancient civilizations. These strong fibers were long and water-resistant.  
Understanding Cannabinoids 
Cannabis plants contain more than five-hundred chemical compounds; cannabinoids, 
terpenes and phenolic compounds15. Terpenes are the aromatic oils that categorize cannabis 
varieties with distinctive flavors like citrus or berry. Terpenes naturally develop on the plant to 
ward off predators and entice pollinators. Their development can be altered by the plant’s 
surrounding environment, such as the climate, soil or fertilizer used. This characteristic allows 
for cultivators to shape and create different strands. Today, terpenes are very diverse. There are 
over one-hundred identified terpenes, ranging from cheese-smelling to floral. The most common 
terpenes are !-pinene and Myrcene (Appendix B). Terpenes are more impressive due to the 
ability to interact with other chemical parts of the plants. 
The other chemical compounds in cannabis are called cannabinoids. These compounds 
are generally the target of scientific research, as they have seemed to offer potential health 
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benefits when unlocked. Cannabinoids naturally occur in the flower’s resin of cannabis plants, 
but today, they can be produced synthetically in the lab. They are fatty components and there are 
over one-hundred and thirteen identified cannabinoids that are separated into three classes: 
endocannabinoids, synthetic cannabinoids, and phytocannabinoids. There are many different 
phytocannabinoids, with the most commonly known ones being delta-9-tetrahydrocannabinol 
(THC), CBD, tetrahydrocannabinolic acid A (THCA), and cannabidolic acid (CBDA)15. THC is 
responsible for the psychotropic properties of cannabis while CBD is non-intoxicating and 
generally known for the therapeutic benefits of cannabis. Strains of cannabis can now be 
cultivated and grown to obtain desired ratios of cannabinoids, such as THC and CBD. Strains 
can be high in THC with a lower concentration of CBD or vice versa. High CBD strains 
generally do not have high euphoric properties and deliver clear-headed functional effects 
instead. The strains that contain high levels of THC can cause people to experience anxiety, 
paranoia and dizziness. THC is most liable for the negative connotations that cannabis receives 
from the public.   
Endocannabinoid System 
 Cannabis would have little to no effect on the human body if it did contain a biological 
system capable of interreacting with the cannabinoids in cannabis. This biological system is 
called the Endocannabinoid System (ECS) and it is a part of the nervous system. It is the main 
component in regulating the body’s homeostasis or maintaining steady internal conditions. 
Cannabinoid receptors, endocannabinoids and metabolic enzymes are the three components that 
make up the ECS. The cannabinoid receptors belong to the G-protein coupled receptor family 
(GPCRs)3. They reside on the surface of cells, transmit information from the brain to the body 
and are responsible for eliciting appropriate cellular responses. Over the years of research, only 
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two cannabinoid receptors have been identified and accepted: CB1 and CB265. CB1 is 
predominantly present in brain and spinal cord and it is one of the most abundant receptors in the 
brain. This receptor specifically regulates functions when the body is under the influence of 
cannabis. It regulates sleep, appetite, time perception and coordination24. The other receptor, 
CB2, are most abundant outside the nervous system, such as on cells in the immune system. This 
receptor regulates pain, inflammation and tissue damage63.  
 Humans produce endogenous cannabinoids called endocannabinoids. Endocannabinoids 
are molecules that bind to the cannabinoid receptors and activate them, eliciting intracellular 
signaling2. Unlike cannabinoids in cannabis, endocannabinoids are produced naturally by the 
cells in the human body. There are also two major endocannabinoids: anandamide and 2-
arachidonylglycerol (2-AG). They have been identified as having a role in pain modulation, 
control of movement, feeding behavior, mood, bone growth, inflammation and memory11. From 
what we know about the endocannabinoid system, it has been suggested that the chemical 
compounds of cannabis react with these specific endocannabinoid receptors throughout the 
human body and produce pharmalogic effects in the nervous and immune system.  
MARIJUANA AS MEDICINE 
 Medical cannabis refers to the use of cannabis, specifically the cannabinoids due to their 
interactions with the human body, as a medical therapy to treat both physical and mental health 
aliments. Medicinal cannabis is administered with the intention of alleviating pain caused by 
diseases and illnesses such as: multiple sclerosis (MS), depression, anxiety, HIV, nausea and 
vomiting associated with chemotherapy, PTSD, epilepsy or opioid addiction37. Currently, there is 
enough substantial evidence to conclude that when administered, cannabis can help the treatment 
of chronic pain, nausea and vomiting associated with chemotherapy, and it can relieve the 
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spasticity episodes associated with multiple sclerosis. There is limited evidence that suggests 
cannabis can help with improving individuals’ sleep patterns in illnesses such as sleep apnea or 
fibromyalgia that can negatively affect their quality of sleep. There is not enough evidence 
available to prove that cannabis has any ability to increase appetite or treat weight loss 
associated with HIV/AIDS, improve Tourette episodes, improve the anxiety of social anxiety 
disorders, nor the ability to improve symptoms of posttraumatic stress disorders.  The call for 
clinical trials to observe these outcomes are necessary in order to determine conclusions 
regarding the desired subjects42. 
The limited clinical evidence that is available suggests that CBD specifically has various 
medical benefits. It can be used to help people with appetite loss from cancer or HIV, chronic 
pain, epilepsy, inflammation, sleep disorders, symptoms from MS, Crohn’s disease, and is 
currently being tested in more debilitating diseases12. CBD has especially become popular 
because it has no lethal dose or any known serious medical side effects. CBD dosages, 
recommended by the Mayo Clinic, are based on the available scientific research, including 
publications and expert opinions12. For example, cancer patient that experience loss of appetite 
are prescribed two and half milligrams of THC to be administered orally accompanied with one 
milligram of CBD oil for six weeks. Patients with chronic pain are recommended anywhere from 
two to twenty milligrams of oral CBD while patients with sleep disorders are recommended 
anywhere up to one-hundred milligrams12.  MS patients use an oral, cannabis-based spray 
containing anywhere from two milligrams to one-hundred and twenty milligrams of a THC/CBD 
complex. This spray is recommended to be used forty-eight times a day for fifteen weeks12. 
However, dosages can fluctuate depending on the patient’s tolerance and request. 
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However, the FDA has not approved cannabis as a safe and effective drug for any 
indication20. They have only approved one medication, Epidiolex which contains pure CBD to 
treat seizures associated with Lennox-Gastaut syndrome (pediatric epilepsy) and two drugs that 
contain synthetic versions of cannabinoids substances that are naturally occurring in cannabis. 
Despite cannabis being illegal at the federal level, many states have officially legalized cannabis 
for medicinal purposes allowing numerous doctors, researchers and patients to take advantage of 
it. 
Qualifying for Medical Marijuana 
 For patients to be administered medical cannabis in a state where it is viable, they must 
first qualify for a medical marijuana card. In order to do so, patients must first meet with a 
certified doctor in order to have their condition(s) assessed. The certified doctor must diagnose 
the patient’s aliment and determine if it is an ailment that is on their state’s list of qualifying 
medical cannabis conditions. If so, the doctor recommends medical cannabis for the patient and 
completes a form for the patient. Once the patient gets approval from a certified doctor, they 
must then apply to their state or county’s medical cannabis program. They must schedule an 
appointment and bring a completed application, government ID, proof of living, money for 
qualifying fees and the verified form from their physician20. Once they are accepted into their 
state or county’s medical marijuana program, they are administered a medical marijuana card 
which authorizes the patient to visit dispensaries and purchase medical cannabis products. The 
card is valid for a year and the patient must reapply forty-five days prior to the card’s expiration 
date by submitting to the previous process. Application requirements vary with each program. 
Accessibility and qualifications for a medical marijuana card also vary state-to-state. In 
some states, only patients with serious and debilitating conditions are allowed access to medical 
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marijuana, such as Alabama, while other states have a long list of qualifying conditions, such as 
Alaska. Additionally, the availability of medical cannabis products varies as well. For example, 
in Ohio, it is illegal to smoke the cannabis flower itself; only concentrates, edibles, vaping and 
oils can be administered to patients that qualify for medicinal cannabis43. In Tennessee, the only 
legal medical cannabis product is CBD oil32. 
Cannabis and Epilepsy 
As previously stated, clinical data and research has suggested that cannabis can help with 
various serious diseases and pain management. There is significant evidence demonstrating a 
positive relationship between cannabis and seizure disorders. One in every twenty-six Americans 
develop epilepsy within their lifetime and there are over 3.4 million people who suffer from the 
crippling disease64. Most forms of epilepsy cannot be treated with over the counter 
medications15. Therefore, it is common for most states to approve epilepsy and seizure disorders 
as qualifying conditions for medical cannabis. Cannabis, specifically CBD, is recognized for its 
anti-seizure properties and it has been shown to reduce the frequency of seizures16. Epidiolex 
was the first FDA-approved cannabis-based drug released to all fifty states in the United States 
to treat epileptic syndromes16. In order to use it, patients must be two-years old or older and have 
not had success with other treatment drugs in the past. Epidiolex is a clear, oral solution that 
contains 100 mg/mL of cannabidiol (CBD) concentrate. Patients start by taking an oral dose of 
2.5 mg/kg Epidiolex twice a day. After one week, the dosage is increased to 5 mg/kg twice daily. 
Furthermore, dosages can be changed based on the individual’s response and tolerability16. Like 
most antiepileptic drugs, including Epidiolex, data suggests that patients should stop usage if 
they experience sedation, suicidal behavior, or any other adverse health effects. However, while 
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Epidiolex is FDA-approved and classified as a Schedule V substance, cannabis and CBD remain 
in Schedule I. 
In 2013, an eight-year-old girl from Colorado, named Charlotte Figi, was treated with 
medical cannabis in order to alleviate her rare and debilitating Dravet syndrome. Charlotte’s 
form of epilepsy was unable to be treated with other medications, but she found that cannabis 
significantly reduced her seizures. Charlette’s public story sparked scientific research to provide 
considerable evidence that cannabis could be an effective, alternate medication for treating 
epilepsy. In 2016, The Lancet Neurology journal released an article confirming that cannabidiol 
has the potential to reduce seizure frequency and “…might have an adequate safety profile in 
children and young adults with highly treatment-resistant epilepsy.”15 The article also pressed the 
need for further investigations to be conducted. Additionally, in another case study, various 
parents of children with some form of epilepsy were surveyed about their opinion on the use of 
cannabidiol-enriched cannabis as a treatment plan45. Eighty-four percent of parents reported that 
their child’s seizure frequency reduced when taking cannabidiol. Eleven percent of these parents 
reported complete seizure freedom45. The parents also reported that their child experienced 
increased alertness, better moods, and sleep improvement. However, like most clinical data 
published research, it concluded with, “safety and tolerability data for cannabidiol-enriched 
cannabis use among children are not available. Objective measurements of a standardized 
preparation of pure cannabidiol are needed to determine whether it is safe, well tolerated, and 
efficacious at controlling seizures in this pediatric population with difficult-to-treat seizures.”45 
Cannabis and Cancer  
Medicinal cannabis is also often used to treat cancer patients in hopes to help alleviate 
the horrible side effects of the disease2. Chemotherapy-induced nausea, inflammation, loss of 
 
17 
appetite and general pain can be treated with the help of cannabis. The licensed and FDA-
approved drugs, dronabinol and nabilone, can be administered to treat such side effects. 
Dronabinol is a synthetically-produced delta-9-THC while nabilone is a synthetic derivative of 
delta-9-THC. These medications are typically prescribed to cancer patients who have not had 
success with previous treatment drugs for chemotherapy side-effects. The recommended dosage 
of nabilone is determined based on the patient. However, the common dose of is one to two 
milligrams orally taken twice a day. When the body is getting use to the drug, it is common for 
patients to experience dizziness, fog-brain and headaches2. Dronabinol is a liquid medication 
also taken orally up to four to six times a day, once again, based on the patient’s tolerance to the 
drug. However, dronabinol can be addictive. If patients stop the use of dronabinol, the possibility 
of withdrawal symptoms, such as trouble sleeping or irritability, can be seen2. 
It has been proven by various clinical studies that THC is an effective antiemetic—a drug 
effective against vomiting and nausea. In a study conducted in 1980, it was concluded that THC 
was an effective antiemetic in many cancer patients that were receiving chemotherapy in 
addition to patients for which other antiemetics were ineffective31. THC proved to be more 
effective in treating vomiting and nausea compared to both the placebo and another treatment 
drug, prochlorperazine, in a “randomized, double-blind, crossover trial with patients who had 
failed to benefit from standard antiemetic therapy”51. These test patients also preferred THC over 
placebo and prochlorperazine. In 2014, a poll from WebMD expressed that eighty-two percent of 
oncologist believed that patients should have access to cannabis2. In addition to pain 
management from side effects of cancer, it has recently been under question if cannabis 
influences shrinking tumors or slowing cancer growth. In a scientific article titled, “A pilot 
clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma 
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multiforme”, suggested that THC inhibited tumor-cell proliferation in vitro and decreased tumor 
cell Ki67 (cancerous) when immunostaining26. However, due to research restrictions, only a total 
of nine individuals were tested. The study also concluded that THC is most likely not the best 
cannabinoid to use for antitumoral studies. There are countless studies available that discuss the 
progression of cannabis associated cancer repercussions, however, the cannabis prohibition at 
the federal level continues to delay further investigation and evidence. There is not enough 
research to convince oncologists to recommend the herbal plant over medications that they have 
seen work, possibly withholding relief from thousands of patients26. Seattle Cancer Alliance 
completed a cross-sectional survey of cancer patients in the Washington area and found that 
seventy-four percent of the examined patients stated that they wanted to know more information 
about cannabis and its uses from their cancer team but only fifteen percent reported receiving 
information from their physicians11. 
Cannabis and Multiple Sclerosis 
 Some of the strongest advocates for the cannabis movement are patients with multiple 
sclerosis. Multiple sclerosis (MS) is a disabling disease of the central nervous system that 
disrupts the flow of information from the brain to the rest of the body. Cannabis helps treat 
common symptoms such as pain, inflammation, muscle spasms, abdominal discomfort and 
depression. The recent research conducted on MS and cannabis has suggested that cannabis 
helps mediate the pathogenetic mechanisms and symptoms of related to MS. The American 
Academy of Neurology conducted a study in 2014 that concluded that an oral cannabis spray 
was most effective in treating these symptoms when compared to nabiximols or synthetic THC44. 
The oral spray was more effective in improving spasticity and pain. Synthetic THC and smoked 
cannabis did not produce enough evidence to determine the effectiveness of each44. In addition, 
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they discovered that both the oral spray and synthetic THC were effective in reducing the 
amount of bladder voids per day. However, neither THC nor oral cannabis proved to be effective 
for tremors44. Additionally, strains that contain higher ratios of CBD relative to THC have 
positive effects on muscle spasticity and pain caused my MS50. However, there is not enough 
information available from clinical research trials to truly decipher the effectiveness on cannabis 
with MS. 
Cannabis and Mental Illness 
 The relationship between cannabis and mental illnesses can be complex. Many believe 
that cannabis induces mental illnesses such as anxiety, depression or suicidal-behavior while 
others argue cannabis improves mental illness symptoms. However, there is not enough 
supporting evidence on either side due to the lack of research. Generally, the only trials 
completed on cannabis and mental illness is obtained through the general public, when cannabis 
users self-administer outside of a laboratory setting or with a medical recommendation of 
cannabis through a physician in a medical cannabis program. 
The National Institute of Mental Health has stated that eighteen percent of Americans 
eighteen and older are affected by anxiety disorders7. Since the endocannabinoid system is 
believed to be responsible for regulating moods and eradicating aversive memories, many have 
made cannabis a popular alternative to prescription medications to treat anxiety-related 
symptoms. Preclinical evidence suggest that CBD can effectively treat anxiety-related disorders 
when orally administered at dosages ranging from fifteen to sixty milligrams7. Additionally, 
Emily O’Brien is the founder of Mondo, a company that sells a cannabis-based powder to treat 
anxiety symptoms. This powder allows victims of anxiety to obtain relief through micro-dosing 
cannabis. Patients are able to precisely measure the amount of THC to the milligram so that they 
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can obtain the therapeutic effects of cannabis without reducing their mental dexterity. O’Brien 
believes the microdosing of cannabis is a technique that will be implemented in the future of 
prescription-drug replacement because it is relief without intoxication and chemicals35. 
Microdosing or acute dosages of cannabis and CBD have the potential to become a treatment for 
anxiety disorders, but, due to the lack of research and understanding on cannabinoid mechanisms 
and the relationship between cannabis and anxiety, it remains questionable. 
 Cannabis has also become in question for its ability to treat physiological illnesses, such 
as depression. The current American treatment of this illness includes prescription 
antidepressants. However, antidepressants can take weeks to take effect and patients can 
experience additional adverse side effects. When compared to these drugs, cannabis works fast 
to stimulate the endocannabinoid system and has little side effects. A study conducted by McGill 
University found that high dosages of THC worsened depressions symptoms while low dosages 
of THC produced serotonin in the brain, helping relieve depression symptoms33. This is one of 
the first studies to conducted on cannabis and depression and provide evidential research 
confirming cannabis can positively affect people suffering from depression or symptoms of 
depression. Besides this study, there is little evidence that cannabis or derivatives of cannabis 
can be effective in reducing depressive symptoms33. The lack of research on cannabis and 
depression also creates a deficient amount of research on the role of cannabis with suicidal 
behaviors. If cannabis were known to cure or treat depression, it could then be used to help 
reverse suicidal behavior. Proponents of utilizing cannabis to battle depressive thoughts claim 
that cannabis helps them battle life stressors and allows them to see things in a positive light31. 
Yet, once again, there is a lack of scientific trials and evidence on this topic. 
Cannabis and Opioid Addiction 
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 One of the leading causes of accidental death in the United States are from prescription 
drug overdoses. According to the NIH, more than one-hundred people die each day from 
overdoses in the United States49. This serious national crisis has demanded attention and 
interventions. In attempts to decrease the amount of opioid related deaths, many have turned to 
the idea of substituting prescription drugs for cannabis or administering cannabis alongside 
opioid usage. When opioid-users also used cannabis either through edibles, vapors or smoking, 
their opioid use reduced by forty to sixty percent8. Some also admitted that they preferred 
cannabis instead of their prescribed drugs. Cannabis can be a safe, effective and non-addictive 
alternative medicine and the effectiveness of cannabis in pain management and tolerance has 
been proven in previous trials. 
Additionally, the endocannabinoid system and the opioidergic system share similarities within 
the human body, making cannabis an impactful alternative to opioids65. Cannabinoids in 
cannabis reacts with the endocannabinoid system CB1 receptors in order to help alleviate opioid 
withdrawal symptoms and opioid use. Cannabis also has the potential to prevent the chance of 
relapse and reduce the amount of opioid related deaths. However, due the federal barriers on 
cannabis, patients suffering from addictive opioid use are unable to obtain access to medical 
cannabis. There are thousands of people each day struggling with opioid addiction and unable to 
reap the possible benefits that cannabis can administer to addiction. 
RESEARCH STRUGGLES 
Despite the various experimental evidence and data on the effectiveness of cannabis on 
human health and the growing popularity of cannabis in the medical field, it remains a Schedule 
1 drug. This classification has created significant obstacles to research and has hindered further 
understanding of cannabis. The federal barriers instilled for cannabis has made research on the 
 
22 
substance virtually impossible. In fact, scientists have a harder time accessing and creating 
research on cannabis than they do with any other illicit drug. The increasing patterns of cannabis 
use and support have demanded for more information on the drug’s health effects, both negative 
and positive. Yet, the science community has failed to convince the federal government to 
reschedule the substance and federal research policies continue to block externally valid, 
randomized clinical trials on cannabis. Federal barriers including a lack of federal funding, a 
complex research approval process and a shortage of clinical cannabis necessary for conducting 
research, have all attributed to the hindrance of cannabis knowledge, potential and patient relief.  
Administrative Barriers 
Before scientists conduct research on cannabis or its cannabinoids, they must trek 
through a series of review processes with multiple federal agencies. The scientist, or his/her 
sponsor, must first obtain a pre-investigational new drug (IND) number by submitting an IND 
application to the Food and Drug Administration21. The IND is a request for the FDA to 
authorize the investigational drug to be administered to humans. The federal law requires a new 
drug to be approved for marketing before it is transported or distributed across state lines. 
However, when conducting research, the IND acts as an exemption from this rule so the 
investigational drug can be shipped from state to state during clinical trials21. 
In order for the FDA to accept the IND application, the sponsor or physician must prove 
that the drug passes various protocols and provide exclusive information within the application22. 
The IND application must contain the drug’s animal pharmacology and toxicology studies, 
manufacturing information and clinical protocols and investigator information22. The sponsor or 
physician must have data confirming that the drug is reasonably safe for the initial testing in 
humans, manufacturing information that ensures the drug can be easily produced and 
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consistently supplied, detailed protocols regarding the clinical studies that were conducted to 
assess the risks of the drugs, information on the qualifications of the clinical professionals 
responsible for the trials, evidence of  research subjects’ consent, and a review of the study from 
an institutional review board22. All these components must be included to satisfy the FDA 
regulations. Once the IND is submitted, the physician or sponsor must wait thirty days before 
initiating research and beginning the clinical trials. If the FDA determines that the proposed 
research contains potential hazards for the research participants or that the IND is lacking in any 
way, the research will be put on hold until the sponsoring researchers resolve the highlighted 
issues22. The IND application process is tedious, and it forces researchers to follow a regulatory 
path, including continuous check-ins with the agency.  
Supply Barriers 
Researchers conducting clinical research on cannabis or cannabinoids must use federally 
approved cannabis. The research-grade cannabis for scientific study is supplied through the 
National Institute on Drug Abuse (NIDA) Drug Supply Program. The Drug Enforcement 
Administration (DEA) regulates cannabis cultivation for research purposes through license 
requirements and by “establishing annual aggregate production quotas under the authority of the 
1970 Controlled Substance Act.”42 However, the DEA has only offered one license for the 
cultivation of cannabis. This license belongs to the University of Mississippi and since 1968, 
they have been the only facility allowed to provide cannabis for research40. The University of 
Mississippi has a designated plot of land, a twelve-acre farm, where cannabis is grown every few 
years, based on the demands of the substance. The cannabis is harvested and stored in their 
facilities as well, awaiting distribution58.  
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In the past, the cannabis outsourced from the University have been few and limited. 
There was only a certain amount of varieties of the plant. The lacking variety of cannabis 
determined what could actually be researched. Other fields of interest that their cannabis did not 
pertain to were neglected. Additionally, the cannabis produced at the University is “manicured to 
a uniform particle size because it is required to be standardized in various research protocols.”58 
Therefore, the potency of the cannabis grown at the University is weaker when compared to 
cannabis that can be purchased at legal dispensaries. This discrepancy in potency can have an 
obvious effect on researchers’ experiments.  
As mentioned before, the University grows cannabis in accordance to the rate of demand. 
Often times, the cannabis that is unused is confined to a freezer. It is known that the temperature 
at which cannabis is stored can also affect the potency and molecular components of cannabis55. 
Lower temperatures slow the process of decarboxylation of the cannabinoids, essentially 
degrading the desired amount of delta-9-tetrahydrocannabinol (THC), and subsequently affecting 
the quality62. If stored improperly, cannabis can also acquire mold and or yeast. As of now, it 
unclear how yeast and mold affect the plant. There is currently no established standard for 
accepted levels of mold or yeast on cannabis plants, which is quite concerning63. 
In order to obtain the desired cannabis for research, investigators must obtain an 
administrative letter of authorization (LOA) from the NIDA. This letter describes the 
manufacturer’s facilities as well as the characteristics of the desired cannabis needed for the 
research. In addition, the DEA also requires researchers to apply for a DEA registration and site 
licensure in order to confirm that the cannabis they are supplied with is in fact for research 
purposes4. Due to the University being the sole facility to provide federally legal cannabis for 
research, it is no surprise that it cannot provide the array of products, potency nor the quantity as 
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numerous amounts of legal dispensaries24 can. This monopoly creates a bottleneck and further 
delays in necessary research. 
Funding Barriers 
Funding for cannabis research is also an obstacle for researchers. Due to the scheduling 
of cannabis, it is almost impossible for a researcher to receive any substantial amount of federal 
funding. Currently, the NIDA is responsible for funding research for multiple health domains, 
including cannabis research39. However, the NIDA does not pursue or support research 
regarding the potential therapeutic or health benefits of cannabis. Instead, the goal of NIDA is to 
“advance science on the causes and consequences of drug use and addiction and to apply that 
knowledge to improve individual and public health”41. Therefore, it is even harder for 
researchers to obtain federal funding on topics that combat the NIDA’s mission. Additionally, 
the lack of federal funding puts research at a disadvantage. Researchers are unable to keep up 
with the ever-changing pace of the cannabis world, causing a bigger gap in understanding the 
comprehensive health effects of cannabis. Without respectable financial support, the necessary 
research to convince physicians, health professionals and law-makers is scarce and 
underwhelming.   
Achieving the Perfect Dose 
Personalized medication in healthcare is tailed to an individual’s clinical, genetic and 
environmental information. Successful personalized medicine is generally difficult to achieve 
due to the complexity of every individual’s internal matrix. Doctors and patients often struggle 
when finding the perfect balance of cannabis to administer at times due to the absence of 
education on the substance. Yet, this can be combatted by the various applications available for 
patients to experience the medical benefits. Patients have the opportunity strategize with their 
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professional healthcare provider to design a treatment plan most suited to their individual desires 
and concerns. This flexibility has made cannabis a more popular alternative medication. A 
patient can decide for themselves the type of cannabis, the type of product and the potency of 
cannabis that would be best suited for them, with the help of doctor recommendations. Oil 
concentrates, non-intoxicating products containing high traces of CBD (five to twenty percent) 
instead of THC and vaporized-smokeless delivery systems have helped transform the view of 
therapeutic cannabis11.  
However, due to the lack of science and clinical-trial evidence on cannabis, doctors and 
patients are realistically underqualified to determine the adequate dosage, type of delivery, and 
the potency of cannabis. Generally, dosages are determined by the physician and altered base on 
the patient’s reactions and tolerance. Most graduated doctors and medical physicians were not 
introduced to cannabis during their medical education; therefore, most are inexpert to counsel 
patients on correct dosages and different administrations. Over eighty percent of recent medical 
school graduates did not receive any education on cannabis throughout their studies, training, 
residencies or fellowships37. 
In most of the previous trials conducted, CBD and THC were administered by smoking 
or by an oral medication. Smoking is generally effective because the lungs are efficient in 
delivering necessary drugs into the body and it allows the cannabinoids to be administered into 
the human blood steam instantaneously. CBD medication can also be delivered orally by using 
an oil-based capsule3 or an oral spray as mentioned previously. Oral administration is effective 
because it forces the substance to pass through the liver, where it can be easily broken down and 
metabolized. The limited research has already demonstrated evidence proving the medical value 
of cannabis. Once the barriers to cannabis research are lowered, scientists and pharmaceutical 
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companies will turn their interest and efforts into discovering how to administer the drug in order 
to optimize the therapeutic benefits and achieve the highest relief possible for patients. 
Current Consensus 
Cannabis is widely used around the world, from adolescence to the elderly. In the United 
States alone, the recreational or medicinal use of cannabis is slowly becoming more popular and 
considered less of an abhorrence. In 2015, it was estimated that twenty-two million Americans 
used cannabis each month37. Additionally, the same survey conveyed that cannabis usage is 
more prevalent among men than women. Appendix E depicts cannabis usage distributed based 
on demographics in 2015. Today, in states which recognize the medical purposes of cannabis, 
there are more than three-million legal medical marijuana users. Additionally, sixty-two percent 
of Americans support the legalization of cannabis, according a survey conducted by the Pew 
Research Center28. Polls also show that American Democrats support the legalization more so 
than Republicans28. As the public support and state legality of cannabis continue to grow, it is 
expected that the percentage of cannabis acceptance will grow subsequently. There are eleven 
U.S. states where cannabis is currently fully legal: Washington, Vermont, Oregon, Nevada, 
Michigan, Massachusetts, Maine, District of Columbia, Colorado, California and Alaska with 
medicinal cannabis legal in thirty-five states.  
Additionally, many states have decriminalized cannabis or have reduced their laws to 
lower the repercussions of possessing, using or distributing the substance. However, it is a 
continuous battle between federal cannabis laws and state laws, creating challenges and 
confusion how where the line is drawn. Even if cannabis is legal in the state you live in, there are 
federal regulations that still apply. Cannabis cannot be on the premises of federal land such as 
national parks, military bases or ski slopes23. Federal employees are not allowed to use cannabis. 
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Students whom receive federal financial aid could lose their funding if they are affiliated with 
cannabis as well as people who live in federally subsidized housing. Additionally, cannabis 
users can be rejected from purchasing a firearm due to the federal regulations on cannabis. The 
failure to comply with federal regulations of cannabis can still face detrimental repercussions23.  
FUTURE OF CANNABIS 
Unfortunately, to this date, the medical use of cannabis remains controversial in the 
United States. Despite the research evidence available from case studies, personal accounts and 
observations, there is not enough high-impact clinical evidence accepted by the FDA. Therefore, 
cannabis continues to be federally outlawed and deemed a Schedule 1 drug, the highest level of 
prohibition for a substance. In addition, there is currently no accepted medical use of cannabis 
by the FDA, therefore, it will continue to be unapproved by the FDA until that is accomplished. 
Federal restrictions limit the necessary research and evidence, further creating a barrier to our 
understanding of the potential benefits and risks that cannabis has to offer.  
The basic and clinical research on cannabis that is legal today is expensive as well as 
exceedingly and unnecessarily difficult to conduct. The federal barriers instilled on cannabis 
hinders the advancement of knowledge on the substance, causing for the therapeutic effects and 
health risks associated with cannabis to remain unknown. With wide-spread state legalization 
under consideration, a demand for appropriate research and knowledge is important now more 
than ever. Federal barriers need to be reviewed and lowered in order for clean cannabis to be 
more accessible for research and for us to finally fill the void of what we don’t know about 
cannabis benefits and harms. Until then, cannabis research and federal agencies remain in a 
‘Catch-22’ scenario. 
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People are still pushing for progression in cannabis research because of all of the 
uncertainties. There are numerous components to cannabis that we still do not understand. The 
complete mechanisms of cannabis are not completely understood and there are hundreds of 
cannabinoids that are still unknown to science. We do not know how many exact cannabinoids 
there are, and we do not know what a lot of them do. There could be hidden cannabinoids that 
possess greater health and therapeutic benefits that are waiting to be discovered. 
 Without this knowledge, we are unable to fully grasp the implication and benefits cannabis 
when interacting with the human body. There is very limited evidence that supports or opposes 
the effects of cannabis with depression, anxiety, epilepsy and MS. Additionally, preliminary 
studies on cannabis with cancer cells, pregnancy, diabetes, and heart health are also necessary 
but cannot be completed due to the mentioned federal barriers. Other issues of incomplete 
cannabis research are that are unable to understand the correct dosages of cannabis. Personalized 
cannabis treatment is currently unobtainable. Therefore, patients are withheld from possibly 
achieving the optimal relief from cannabis. If cannabis were to be understood at a higher level, 
personalized strains with desired ratios of THC and CBD (or other cannabinoids) could be 
achieved.  
In addition, it is important to recognize that the previous work completed in clinical trials and 
evidence were completed following federally recognized regulations. All of the cannabis 
research completed thus far has been conducted using one single source of cannabis, from the 
NIDA’s supply at the University of Mississippi. This cannabis is known to be low in potency 
and quality, causing the resultant research to contain possible errors and the possibility to have 
little validity in modern day cannabis life. 
 
30 
The overall gaps in our knowledge on cannabis dosages, cannabinoid content and ratios, 
contradictions, misuse liability, effectiveness of different administrations, cannabinoid 
mechanisms, cannabinoids, bioavailability and many other unanswered questions continue to 
stimulate a negative stigma towards cannabis. The federal government and agencies also 
promote this negative stigma of cannabis by rejecting any information from trials that were not 
federally-approved and withhold publishing medical benefits of cannabis to the general public. 
The federal labeling of cannabis, funding barriers, and lack of access to real-life cannabis in 
clinical research and studies contribute our inability to fill the void in our comprehension on 
cannabis. As cannabis use becomes more prevalent, it is imperative that we understand how it 
can impact our bodies and our society. 
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Appendix 
Appendix A: 
 
Figure 1: Visual difference in morphological features between C. sativa and c. indica. 
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Appendix B: 
 
 
Figure 2: This table serves as a guide for the eight, most common terpenes found in cannabis. 
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Appendix C: 
 
Figure 3: This table summarizes the steps described on the U.S. federal Food and Drug 
Administration for the process required for any cannabis research. 
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Appendix D: 
 
Figure 4: Depiction of the legality of cannabis in the United States. 
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Appendix E: 
 
Figure 5:  Past-Month usage of cannabis by Demographic in 2015. Table taken from National 
Academies of Sciences.
 
